Re: Ming Yuen Teo, Jose Mauricio Mota, Karissa A. Whiting, et al. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. Eur Urol 2020;78:907-15 Linking FGFR3 Mutation Status and Luminal Papillary Subtype to Response to Cisplatin-based Chemotherapy in Bladder Cancer

Roumiguie Mathieu; Contreras-Sanz Alberto; Black Peter C.

首页> 外文期刊>European urology >Re: Ming Yuen Teo, Jose Mauricio Mota, Karissa A. Whiting, et al. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. Eur Urol 2020;78:907-15 Linking FGFR3 Mutation Status and Luminal Papillary Subtype to Response to Cisplatin-based Chemotherapy in Bladder Cancer

【24h】

Re: Ming Yuen Teo, Jose Mauricio Mota, Karissa A. Whiting, et al. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. Eur Urol 2020;78:907-15 Linking FGFR3 Mutation Status and Luminal Papillary Subtype to Response to Cisplatin-based Chemotherapy in Bladder Cancer

机译：Re：Ming Yuen Teo，Jose Mauricio Mota，Karissa A. Whiting等。成纤维细胞生长因子受体3改变状态与局部晚期和转移性尿路上皮癌的铂化疗的差异敏感性相关。 EUR UROL 2020; 78：907-15连接FGFR3突变状态和腔乳头状亚型，以应对膀胱癌的顺铂化疗

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European urology》 |2021年第6期|共2页
作者
Roumiguie Mathieu; Contreras-Sanz Alberto; Black Peter C.;
展开▼
作者单位

Ctr Hosp Univ Toulouse Dept Urol 1 Ave Jean Poulhes F-31059 Toulouse France;

Univ British Columbia Vancouver Prostate Ctr Dept Urol Sci Vancouver BC Canada;

Univ British Columbia Vancouver Prostate Ctr Dept Urol Sci Vancouver BC Canada;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类泌尿科学（泌尿生殖系疾病）;
关键词

相似文献

外文文献

1. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma (vol 78, pg 907, 2020) [J] . Teo Min Yuen, Mota Jose Mauricio, Whiting Karissa A., European urology . 2021,第5期

机译：成纤维细胞生长因子受体3改变状态与基于铂的化学疗法的差异敏感有关（Vol 78，PG 907,2020）
2. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma [J] . Teo Min Yuen, Mota Jose Mauricio, Whiting Karissa A., European urology . 2020,第6期

机译：成纤维细胞生长因子受体3改变状态与局部晚期和转移性尿路上皮癌的铂化疗的差异敏感性相关
3. Reply to Pontus Eriksson, Gottfrid Sj?dahl, and Fredrik Liedberg's Letter to the Editor re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48–55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder Cancer is Also Needed [J] . Thomas Powles, Alfonso Gómez de Lia?o, Charlotte Ackerman European urology . 2017,第5期

机译：回复Pontus Eriksson，Gottfrid SJ？Dahl，以及Fredrik Liedberg的信Re：Thomas Powers，Robert A. Huddart，Tony Elliott等。 III期，双盲，随机试验，将Lapatinib与安慰剂进行比较患者人体表皮生长因子受体1/2阳性转移性膀胱癌的一线化疗后的安慰剂。 J Clin Oncol 2017; 35：48-55。知道HER2状态是不够的：还需要一种分子亚型对膀胱癌的方法

著录项

相似文献

相关主题

期刊订阅